Bristol to divest Celgene's psoriasis treatment in FTC clearance push
June 24, 2019 at 07:45 AM EDT
Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).
